Key result
Abstract lacks persistence results for valbenazine versus deutetrabenazine-XR in tardive dyskinesia.
Why the study?
Does valbenazine improve persistence outcomes compared to deutetrabenazine XR in patients with tardive dyskinesia?
Does valbenazine improve persistence outcomes compared to deutetrabenazine XR in patients with tardive dyskinesia?
Abstract lacks reported persistence outcomes; leaves open optimal VMAT2 inhibitor selection in tardive dyskinesia.
Evaluate persistence outcomes among matched deutetrabenazine-extended-release (XR) and valbenazine cohorts.
No takes yet. Share an insight, caveat, or question.
Doshi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: